Discloses use of hyaluronic acid (HA) and mesalamine, or a HA mixture and mesalamine in the manufacture of pharmaceutical composition for treating or preventing mucosal inflammation related disorder in a mammal or human, wherein the pharmaceutical composition is formulated for administering a dose of mesalamine of from 250 mg to 1 g per day.